Category: Medmonitor

98 posts found

Suzetrigine’s Early Impact for Pain Management

Data presented at PAINWeek 2026 indicates that the novel, non-opioid pain medication may be shaking up prescribing patterns for acute pain.

Medmonitor

Novel Drug Approvals Supported by Fewer Studies

A study from PLOS One examined trends in drug approvals before and after implementation of new federal regulations for evidentiary standards.

Medmonitor

Generic Drug Tariffs Announced for 2028

A 100% tariff will take effect August 1, 2028 for generic drugs imported into the U.S., followed by a 200% tariff in August 2029.

Medmonitor

FDA Approves Rextovy as OTC for Opioid Overdose

This approval marks the third OTC naloxone medication available for the treatment of opioid overdose.

Medmonitor

Can GLP-1 Drugs Lower Cancer Risks?

While experts agree more research is needed, several studies have noted patients on these drugs showed reduced rates of certain types of cancer.

Medmonitor

FDA Approves New Oral GLP-1 Tablets, Foundayo, for Treatment of Obesity

The once-daily tablet starts at an 0.8 mg dosage, which is then steadily increased at 30-day intervals, based on treatment response and tolerability.

Medmonitor

FDA Approves Oral Tablet Formulation of Wegovy

This approval marks the arrival of the first oral GLP-1 semaglutide drug.

Medmonitor

CMS Drug Pricing Negotiation to Lower Costs of 15 Drugs

The 2025 negotiations covered drugs for obesity, cancer, diabetes, COPD, asthma, and more.

Medmonitor

White House Announces Deal to Expand Access to GLP-1 Medications

Qualifying CMS patients could pay as little as $50 a month for Ozempic or Wegovy.

Medmonitor

New Osteoporosis Biosimilar Approved

Enoby™ (denosumab-qdbe) injections are a biosimilar of Prolia^®, to help increase bone mass in those with high risk of fracture.

Medmonitor

Generic Saxenda Delivers First GLP-1 Generic for Obesity

The approval of generic liraglutide injections address increased demand for GLP-1 receptor antagonist drugs.

Medmonitor

FDA Orders Opioid Manufacturers to Update Prescribing Information for Long-Term Use

All opioid manufacturers must update their drug labeling to align with a list of notes provided by the FDA.

Medmonitor

FDA Requires New Kidney Injury Warning for All GLP-1 Drugs

Dehydration from these drugs can lead to kidney damage, requiring hemodialysis treatment.

Medmonitor

Brekiya Approved for the Acute Treatment of Migraine

Dihydroergotamine mesylate injections are approved for the acute treatment of migraine with or without aura, and for the acute treatment of cluster headaches.

Medmonitor

FDA Approves a New Migraine Medication

Atzumi™ (dihydroergotamine (DHE)) nasal powder was approved for the treatment of acute migraine.

1 2 3 4 5 6 7 Next